Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Venous Thromboembolism 7Venous Thrombosis 5Pulmonary Embolism 4Neoplasms 4Thromboembolism 2Lung Neoplasms 2Thrombosis 1Thrombocytopenia 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1Hemorrhage 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × Tinzaparin × Clear all
NCT00293501 2013-11-06

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1/2 Unknown
35 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡